Cargando…

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs

Detalles Bibliográficos
Autores principales:	Abassi, Zaid, Armaly, Zaher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2015
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336840/ https://www.ncbi.nlm.nih.gov/pubmed/25880290 http://dx.doi.org/10.5152/akd.2015.15072

Ejemplares similares

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Preeclampsia: Novel Mechanisms and Potential Therapeutic Approaches
por: Armaly, Zaher, et al.
Publicado: (2018)

Nephroprotective Effect of Heparanase in Experimental Nephrotic Syndrome
por: Assady, Suheir, et al.
Publicado: (2015)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Acute kidney injury following isotretinoin treatment
por: Armaly, Zaher, et al.
Publicado: (2013)

ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle
por: Abassi, Zaid, et al.
Publicado: (2020)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Nephroprotective Properties of Antidiabetic Drugs
por: Gerdes, Christian, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors after left ventricular assist device: no free lunch?
por: Grandin, E. Wilson, et al.
Publicado: (2021)

Is nitric oxide the forgotten nephroprotective treatment during cardiac surgery?
por: Khorashadi, Mina, et al.
Publicado: (2020)

“The new normal”? Lessons from the treatment of emerging infectious diseases with old drugs
por: Baptista, Maria João
Publicado: (2022)

Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545
por: Abassi, Zaid, et al.
Publicado: (2017)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
por: Garofalo, Carlo, et al.
Publicado: (2019)

Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. Diabetes Care 2022;45:35–41
por: Heyman, Samuel N., et al.
Publicado: (2022)

XBB.1.5 emerges in the Americas: what it means to the region
por: Hotez, Peter
Publicado: (2023)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Emerging Therapies for Dystrophic Cardiomyopathy
por: Garry, Daniel J., et al.
Publicado: (2019)

The history of the cardiac emergency room, and the patient’s history
por: Peters, R. J. G.
Publicado: (2014)

The Emerging Role of Circular RNAs in Cardio-Oncology
por: Gao, Chen, et al.
Publicado: (2023)

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV‐INHIBITION study design
por: Amedro, Pascal, et al.
Publicado: (2020)

Role of Echocardiography in Diagnosing Myocardial Ischemia at Emergency Department
por: Cho, Kyoung Im
Publicado: (2017)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

The Art of War in Drug Development
por: Kariya, Taro, et al.
Publicado: (2019)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancer
por: Morris, Luc G.T., et al.
Publicado: (2011)

TGF-β Inhibitor CILP as a Novel Biomarker for Cardiac Fibrosis
por: Groß, Sonja, et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Pulmonary Arteriovenous Malformations and the Hepatic “Black Box”: Are We Emerging From the Darkness?
por: Rajagopal, Satish K., et al.
Publicado: (2021)

Identification of specific and semi-specific SIRT inhibitors through computer-aided studies
por: Mai, Antonello
Publicado: (2011)

Cathepsin A Inhibitors to Treat Heart Disease: Much Potential, Many Questions
por: Cowling, Randy T.
Publicado: (2019)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable”
por: Hantschel, Oliver, et al.
Publicado: (2011)

Non vitamin K anticoagulation drugs will win the race
por: Van Gelder, I. C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pg74jbta6ojn0mju599vjqetgd